Trial ID 20133 | Maryland Oncology Hematology Trial ID 20133 – Maryland Oncology Hematology

Trial ID 20133

Trial Information - Phase III

A Phase III, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high-risk patients with previously untreated Diffuse Large B-Cell Lymphoma

Protocol ID: MOR208C310

Sponsor: Morphosys

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lymphoma

Investigator

Narang MD, Mohit

Status

OPEN TO ENROLLMENT

Sponsor

Morphosys

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology